IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

RTTNews | 881日前
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

(RTTNews) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.

Beaupre's extensive career includes various clinical development and translational research roles in industry, including most recently at BioSplice Therapeutics as Chief Medical Officer and Head of Research and Development in Oncology.

Beaupre previously served as Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, Inc., where he led cross-disciplinary groups including clinical development, clinical pharmacology, translational oncology and clinical operations related study clinicians.

Beaupre also served at Pharmacyclics (Abbvie) as Vice President, Head of Early Development and Immunotherapy, and at Amgen as Medical Director.

He was previously an Assistant Professor at the H. Lee Moffitt Cancer Center and Research Institute, and also held various earlier appointments at the University of Miami and the M.D. Anderson Cancer Center.

read more
IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews | 432日前
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 614日前
Swiss Market Ends Modestly Higher

Swiss Market Ends Modestly Higher

The Swiss market closed modestly higher on Friday after moving in a tight bandwith investors digesting earnings updates and continuing to track the developments on the tariff front.
RTTNews | 1日前
European Stocks Close Higher

European Stocks Close Higher

Despite lingering uncertainty about U.S. government's trade policy, European stocks closed higher on Friday, with German and French markets gaining for a fourth straight session, and the U.K. moving up for the tenth consecutive session, as investors focused on earnings.
RTTNews | 1日前
U.S. Consumer Sentiment Deteriorates Modestly Less Than Estimated In April

U.S. Consumer Sentiment Deteriorates Modestly Less Than Estimated In April

A report released by the University of Michigan on Friday showed consumer sentiment in the U.S. deteriorated modestly less than previously estimated in the month of April. The University of Michigan said its consumer sentiment index for April was upwardly revised to 52.2 from a preliminary reading of 50.8. Economists had expected the index to be unrevised.
RTTNews | 1日前